Thermal Ablation of Breast Cancer Liver Metastases Is Associated with Durable Local Control and Chemotherapy-Free Intervals in Selected Patients
Thermische Ablation von Lebermetastasen des Mammakarzinoms ist bei ausgewählten Patient:innen mit dauerhaftem lokalem Kontrollgewinn und chemotherapiefreien Intervallen verbunden
Cancers · 19.06.2026 · 18 (12) · 1997
DOI: 10.3390/cancers18121997 ↗Auf einen Blick
Bei 46 Patient:innen mit BCLM zeigte die perkutane thermische Ablation hohe technische Wirksamkeit und langfristige lokale Kontrolle. Die Intervalle ohne Eskalation der Systemtherapie waren klinisch relevant.
Fragestellung
Welche onkologischen und therapiebasierten Endpunkte werden nach perkutaner thermischer Ablation bei BCLM erreicht?
Methode
Retrospektive Kohortenstudie eines Einzelzentrums; konsekutive Patient:innen nach multidisziplinärer Freigabe zwischen 2005 und 2025; Auswertung nach SIO- und DATECAN-Konsensus.
Ergebnisse
46 Patient:innen, 58 Ablationssitzungen, 80 Metastasen. Primäre/sekundäre Technik-Effizienz 95 % (76/80) bzw. 99 % (79/80). Major-Komplikationen 2/58 Sitzungen (3 %). Medianes OS 44 Monate, PFS 8,3 Monate, TTCST 13 Monate, CFS 16,4 Monate.
Einschränkungen
Einzelzentrische retrospektive Kohortenstudie ohne Vergleichsgruppe.
Schlussfolgerung der Autor:innen
Bei ausgewählten Patient:innen erreichte die perkutane thermische Ablation bei BCLM hohe technische Wirksamkeit, dauerhafte lokale Kontrolle und wenige schwere Komplikationen. Vergleichsstudien sind nötig.
Kernaussagen
- Primäre Technik-Effizienz: 95 % (76/80)
- Lokale Tumorprogression bei 16/79 Tumoren (20 %)
- Medianes CFS: 16,4 Monate
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 19.06.2026. Verfasst von Niaz Ahmed und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: In selected patients with oligometastatic breast cancer liver metastases (BCLM), liver-directed therapies may provide durable local control and may delay escalation of systemic therapy. This study reports a single-center experience of percutaneous thermal ablation (radiofrequency ablation [RFA] or microwave ablation [MWA]) for BCLM, including conventional oncologic outcomes and therapy-based endpoints.
Methods
This retrospective cohort included consecutive patients treated with percutaneous ablation for BCLM following multidisciplinary team approval between 2005 and 2025. Outcomes were defined according to the Society of Interventional Oncology (SIO) and DATECAN consensus terminology. Lesion-level outcomes included primary/secondary technique efficacy and local tumor progression-free survival (LTPFS). Patient-level outcomes included progression-free survival (PFS), overall survival (OS), time to change in systemic therapy (TTCST) and chemotherapy-free survival (CFS). Kaplan–Meier and Cox regression analyses were performed.
Results
Forty-six patients underwent 58 ablation sessions treating 80 metastases (median tumor size 19 mm, interquartile range [IQR] 13–27 mm). Primary and secondary technique efficacy were 95% (76/80) and 99% (79/80), respectively. Major complications occurred in 2/58 sessions (3%). Local tumor progression occurred in 16/79 tumors (20%) after a median follow-up of 28 months; LTPFS rates at 1, 3 and 5 years were 84%, 75% and 75%, respectively. Median OS was 44 months (1-, 3- and 5-year OS 94%, 58%, and 40%), and median PFS was 8.3 months. Median TTCST was 13 months, and median CFS was 16.4 months. Triple-negative disease was associated with worse LTPFS and shorter CFS. Oligopersistent disease was associated with improved PFS compared with oligoprogression.
Conclusions
In this selected cohort, percutaneous thermal ablation for BCLM achieved high technique efficacy, durable local control and low major complication rates. Therapy-based endpoints suggest a clinically meaningful interval without systemic therapy escalation in appropriately selected patients, although comparative studies are needed to quantify the incremental benefit.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
ORCID-Profile: Niaz Ahmed, Alicia Okines, Emma Kipps, Nicos Fotiadis
Zitieren
APA
Ahmed, N., Okines, A., McGrath, S., Parton, M., Kipps, E., Turner, N., Johnston, E., Johnston, S., & Fotiadis, N. (2026). Thermal Ablation of Breast Cancer Liver Metastases Is Associated with Durable Local Control and Chemotherapy-Free Intervals in Selected Patients. Cancers, 18(12), 1997. https://doi.org/10.3390/cancers18121997
Vancouver
Ahmed N, Okines A, McGrath S, Parton M, Kipps E, Turner N, et al. Thermal Ablation of Breast Cancer Liver Metastases Is Associated with Durable Local Control and Chemotherapy-Free Intervals in Selected Patients. Cancers. 2026;18(12):1997. doi:10.3390/cancers18121997
BibTeX
@article{Ahmed2026,
author = {Ahmed, Niaz and Okines, Alicia and McGrath, Sophie and Parton, Marina and Kipps, Emma and Turner, Nicholas and Johnston, Edward and Johnston, Stephen and Fotiadis, Nicos},
title = {Thermal Ablation of Breast Cancer Liver Metastases Is Associated with Durable Local Control and Chemotherapy-Free Intervals in Selected Patients},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1997},
doi = {10.3390/cancers18121997}
}
EUVIMED